Are Medical Stocks Lagging Adicet Bio This Year?
| ACET Stock | USD 0.83 0.02 2.35% |
Slightly above 61% of Adicet Bio's investor base is looking to short. The analysis of overall sentiment of trading Adicet Bio stock suggests that many investors are alarmed at this time. Adicet Bio's investing sentiment can be driven by a variety of factors including economic data, Adicet Bio's earnings reports, geopolitical events, and overall market trends.
Adicet |
Here is how Adicet Bio, Inc. and Adma Biologics have performed compared to their sector so far this year.
Read at zacks.com
 |
Adicet Bio Fundamental Analysis
We analyze Adicet Bio's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Adicet Bio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Adicet Bio based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Asset
Current Asset Comparative Analysis
Adicet Bio is currently under evaluation in current asset category among its peers. Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
Adicet Bio Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Adicet Bio stock to make a market-neutral strategy. Peer analysis of Adicet Bio could also be used in its relative valuation, which is a method of valuing Adicet Bio by comparing valuation metrics with similar companies.
Peers
Adicet Bio Related Equities
| NKTX | Nkarta | 1.52 | ||||
| AVTE | Aerovate Therapeutics | 0.80 | ||||
| EWTX | Edgewise Therapeutics | 0.73 | ||||
| AGIO | Agios Pharm | 1.82 | ||||
| KROS | Keros Therapeutics | 1.82 | ||||
| BCYC | Bicycle Therapeutics | 2.39 | ||||
| VOR | Vor Biopharma | 2.60 | ||||
| PLRX | Pliant Therapeutics | 2.65 | ||||
| ANEB | Anebulo Pharmaceuticals | 2.86 | ||||
| ALEC | Alector | 3.01 | ||||
| GLUE | Monte Rosa | 3.04 | ||||
| IGMS | IGM Biosciences | 3.13 | ||||
| STOK | Stoke Therapeutics | 3.22 | ||||
| CGEM | Cullinan Oncology | 3.26 | ||||
| TNYA | Tenaya Therapeutics | 7.25 | ||||
| ACRV | Acrivon Therapeutics, | 11.11 |
Additional Tools for Adicet Stock Analysis
When running Adicet Bio's price analysis, check to measure Adicet Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adicet Bio is operating at the current time. Most of Adicet Bio's value examination focuses on studying past and present price action to predict the probability of Adicet Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adicet Bio's price. Additionally, you may evaluate how the addition of Adicet Bio to your portfolios can decrease your overall portfolio volatility.